Comparative Pharmacology
Head-to-head clinical analysis: FANAPT versus SAPHRIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FANAPT versus SAPHRIS.
FANAPT vs SAPHRIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FANAPT (iloperidone) is an atypical antipsychotic that exhibits high affinity for serotonin 5-HT2A and dopamine D2 receptors, with additional antagonism at alpha1-adrenergic, alpha2-adrenergic, and histamine H1 receptors. The therapeutic efficacy is primarily attributed to combined 5-HT2A and D2 receptor antagonism.
Asenapine is an atypical antipsychotic with high affinity for serotonin 5-HT2A, 5-HT2C, 5-HT6, and 5-HT7 receptors; dopamine D2, D3, and D4 receptors; and alpha2-adrenergic receptors. It also has moderate affinity for histamine H1 and alpha1-adrenergic receptors, and low affinity for muscarinic M1 receptors.
12-24 mg orally once daily, titrated from 1 mg twice daily on day 1, 2 mg twice daily on day 2, 4 mg twice daily on day 3, 6 mg twice daily on day 4, 8 mg twice daily on day 5, then 10 mg twice daily on day 6 and 7, followed by 12 mg once daily on day 8. Maximum dose: 24 mg/day.
5 mg sublingually twice daily, may increase to 10 mg twice daily based on tolerability and efficacy.
None Documented
None Documented
Terminal elimination half-life is approximately 26 hours (range 22-30 hours) for the sum of parent drug and active metabolites (P95, P88, and P86); steady-state achieved within 4-5 days.
Terminal elimination half-life is 30-40 hours, supporting once-daily dosing.
Renal (approximately 80% as metabolites, <1% as parent drug) and fecal (approximately 20% as metabolites).
After oral administration, approximately 50% of the dose is excreted in urine (mostly as metabolites, <1% unchanged) and 40% in feces (mostly as metabolites).
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic